The Advantages of Multi-Epitope Tumor Antigens as an Approach to Treating Breast Cancer
Annual rept. 1 Jul 1998-30 Jun 1999
CALIFORNIA UNIV LOS ANGELES
Pagination or Media Count:
Dendritic cells DC are an integral part of the immune systems response to cancer. A number of clinical trials have been initiated to use these cells in the treatment of melanoma, prostate cancer, and lymphoma. In preparation for treating breast cancer patients with DC, this proposal examines a fundamental issue that needs to be resolved before proceeding with this exciting new therapy. We hypothesized that the processing and presentation of multiple tumor antigen epitopes by DC is a more efficient and effective way of stimulating T cell responses than current HLA-restricted peptide-based methods. The goal of this proposal is to develop practical methods by which immune cells from patients with breast cancer can be used to promote effective anti-tumor responses. In the past year we have begun recruiting patients for in vitro studies of antigen-presentation and have optimized testing procedures to evaluate anti-tumor cytotoxicity and tumor antigen-specific cytokine release by T cells. In addition, we have devised a strategy for expressing the Her-2 gene in DC and evaluated methods for preparing tumor lysate and whole tumor antigen. This progress is consistent with the proposals Statement of Work, and leaves us well-positioned to achieve the next goals of the proposal.
- Anatomy and Physiology
- Medicine and Medical Research